| Type | MGI:General | Description | 76% of females develop asynchronous mammary tumors with an average latency of 28.2 weeks, with the earliest onset at 23 weeks of age females treated with an anti-ERBB2 antibody, mu4D5, show reduced mammary tumor incidence and inhibition of tumor growth |
